300 related articles for article (PubMed ID: 15345784)
1. Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons.
Ammassari A; Antinori A; Aloisi MS; Trotta MP; Murri R; Bartoli L; Monforte AD; Wu AW; Starace F
Psychosomatics; 2004; 45(5):394-402. PubMed ID: 15345784
[TBL] [Abstract][Full Text] [Related]
2. Depression and neurocognitive performance in individuals with HIV/AIDS: 2-year follow-up.
Gibbie T; Mijch A; Ellen S; Hoy J; Hutchison C; Wright E; Chua P; Judd F
HIV Med; 2006 Mar; 7(2):112-21. PubMed ID: 16420256
[TBL] [Abstract][Full Text] [Related]
3. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
[TBL] [Abstract][Full Text] [Related]
4. Neurocognitive impairment influences quality of life in HIV-infected patients receiving HAART.
Tozzi V; Balestra P; Murri R; Galgani S; Bellagamba R; Narciso P; Antinori A; Giulianelli M; Tosi G; Fantoni M; Sampaolesi A; Noto P; Ippolito G; Wu AW
Int J STD AIDS; 2004 Apr; 15(4):254-9. PubMed ID: 15075020
[TBL] [Abstract][Full Text] [Related]
5. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
[TBL] [Abstract][Full Text] [Related]
6. The effect of depressive symptoms at ART initiation on HIV clinical progression and mortality: implications in clinical practice.
Villes V; Spire B; Lewden C; Perronne C; Besnier JM; Garré M; Chêne G; Leport C; Carrieri MP; Le Moings V;
Antivir Ther; 2007; 12(7):1067-74. PubMed ID: 18018765
[TBL] [Abstract][Full Text] [Related]
7. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.
Palepu A; Tyndall MW; Joy R; Kerr T; Wood E; Press N; Hogg RS; Montaner JS
Drug Alcohol Depend; 2006 Sep; 84(2):188-94. PubMed ID: 16542797
[TBL] [Abstract][Full Text] [Related]
8. Antidepressant therapy can improve adherence to antiretroviral regimens among HIV-infected and depressed patients.
Dalessandro M; Conti CM; Gambi F; Falasca K; Doyle R; Conti P; Caciagli F; Fulcheri M; Vecchiet J
J Clin Psychopharmacol; 2007 Feb; 27(1):58-61. PubMed ID: 17224714
[TBL] [Abstract][Full Text] [Related]
9. Neurocognitive functioning and HAART in HIV and hepatitis C virus co-infection.
Parsons TD; Tucker KA; Hall CD; Robertson WT; Eron JJ; Fried MW; Robertson KR
AIDS; 2006 Aug; 20(12):1591-5. PubMed ID: 16868439
[TBL] [Abstract][Full Text] [Related]
10. Depressive symptoms and neurocognitive performance among HIV-infected women.
Fialho RM; Pereira M; Mendonça N; Ouakinin S
Women Health; 2013; 53(2):117-34. PubMed ID: 23517511
[TBL] [Abstract][Full Text] [Related]
11. Neurocognitive aspects of medication adherence in HIV-positive injecting drug users.
Waldrop-Valverde D; Ownby RL; Wilkie FL; Mack A; Kumar M; Metsch L
AIDS Behav; 2006 May; 10(3):287-97. PubMed ID: 16485072
[TBL] [Abstract][Full Text] [Related]
12. Antiretroviral therapy improves cognitive impairment in HIV+ individuals in sub-Saharan Africa.
Sacktor N; Nakasujja N; Skolasky R; Robertson K; Wong M; Musisi S; Ronald A; Katabira E
Neurology; 2006 Jul; 67(2):311-4. PubMed ID: 16864825
[TBL] [Abstract][Full Text] [Related]
13. Effects of HIV-1 infection and aging on neurobehavioral functioning: preliminary findings.
Cherner M; Ellis RJ; Lazzaretto D; Young C; Mindt MR; Atkinson JH; Grant I; Heaton RK;
AIDS; 2004 Jan; 18 Suppl 1():S27-34. PubMed ID: 15075495
[TBL] [Abstract][Full Text] [Related]
14. One-year adherence to clinic visits after highly active antiretroviral therapy: a predictor of clinical progress in HIV patients.
Park WB; Choe PG; Kim SH; Jo JH; Bang JH; Kim HB; Kim NJ; Oh M; Choe KW
J Intern Med; 2007 Mar; 261(3):268-75. PubMed ID: 17305649
[TBL] [Abstract][Full Text] [Related]
15. Medication adherence in HIV-infected smokers: the mediating role of depressive symptoms.
Webb MS; Vanable PA; Carey MP; Blair DC
AIDS Educ Prev; 2009 Jun; 21(3 Suppl):94-105. PubMed ID: 19537957
[TBL] [Abstract][Full Text] [Related]
16. Neurocognitive functioning in pediatric human immunodeficiency virus infection: effects of combined therapy.
Shanbhag MC; Rutstein RM; Zaoutis T; Zhao H; Chao D; Radcliffe J
Arch Pediatr Adolesc Med; 2005 Jul; 159(7):651-6. PubMed ID: 15996999
[TBL] [Abstract][Full Text] [Related]
17. Fatigue in HIV/AIDS is associated with depression and subjective neurocognitive complaints but not neuropsychological functioning.
Millikin CP; Rourke SB; Halman MH; Power C
J Clin Exp Neuropsychol; 2003 Apr; 25(2):201-15. PubMed ID: 12754678
[TBL] [Abstract][Full Text] [Related]
18. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.
Clifford GM; Polesel J; Rickenbach M; Dal Maso L; Keiser O; Kofler A; Rapiti E; Levi F; Jundt G; Fisch T; Bordoni A; De Weck D; Franceschi S;
J Natl Cancer Inst; 2005 Mar; 97(6):425-32. PubMed ID: 15770006
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal antiretroviral adherence among adolescents infected with human immunodeficiency virus.
Murphy DA; Belzer M; Durako SJ; Sarr M; Wilson CM; Muenz LR;
Arch Pediatr Adolesc Med; 2005 Aug; 159(8):764-70. PubMed ID: 16061785
[TBL] [Abstract][Full Text] [Related]
20. Sexual risk behaviour and HAART: a comparative study of HIV-infected persons on HAART and on preventive therapy in Kenya.
Sarna A; Luchters SM; Geibel S; Kaai S; Munyao P; Shikely KS; Mandaliya K; van Dam J; Temmerman M
Int J STD AIDS; 2008 Feb; 19(2):85-9. PubMed ID: 18334059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
